| NCT ID | NCT06989086 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Virginia Commonwealth University |
| Condition | Primary Malignant Brain Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 112 participants |
| Start Date | 2025-06-24 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 112 participants in total. It began in 2025-06-24 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers
Eligibility Criteria
Inclusion Criteria: Patients: * Self-report a diagnosis of a primary malignant brain tumor (grade II-IV) * \>2 weeks post-cranial resection or biopsy * Elevated Fear of Recurrence Distress Rating * Primarily English speaking * \>/= 18 years of age at the time of enrollment Caregivers: * nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV) * Elevated Fear of Recurrence Distress Rating * Primarily English speaking * \>/= 18 years of age at the time of enrollment Exclusion Criteria: Patient / Caregiver Exclusion: * Cognitive impairment that might prohibit active intervention engagement * Inability to understand and provide informed consent * Inability to attend virtual sessions due to unstable or no internet connection
Contact & Investigator
Ashlee R Loughan, Ph.D
PRINCIPAL INVESTIGATOR
Virginia Commonwealth University
Frequently Asked Questions
Who can join the NCT06989086 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Primary Malignant Brain Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06989086 currently recruiting?
Yes, NCT06989086 is actively recruiting participants. Contact the research team at LiveNOW@vcu.edu for enrollment information.
Where is the NCT06989086 trial being conducted?
This trial is being conducted at Richmond, United States.
Who is sponsoring the NCT06989086 clinical trial?
NCT06989086 is sponsored by Virginia Commonwealth University. The principal investigator is Ashlee R Loughan, Ph.D at Virginia Commonwealth University. The trial plans to enroll 112 participants.